Iron Deficiency Anemia Clinical Trial
Official title:
Effects of Nutritional Iron Absorption Enhancers and Inhibitors and Daytime on Absorption From Oral Iron Supplements
NCT number | NCT05414474 |
Other study ID # | IDEA |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 20, 2022 |
Est. completion date | December 9, 2022 |
Verified date | January 2024 |
Source | Swiss Federal Institute of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Iron deficiency (ID) is a major public health problem worldwide and oral iron supplementation can be an effective strategy to treat and prevent ID. To maximize iron bioavailability form oral iron supplements the simultaneous intake of the iron absorption enhancer ascorbic acid (AA) is recommended, and the simultaneous intake of coffee or tea containing the iron absorption inhibitors polyphenols should be avoided. Also, oral iron supplements are recommended to be taken on an empty stomach in the morning and without a meal to avoid any interaction with phytic acid, another iron absorption inhibitor present in many foods. However, the effects of these iron absorption enhancers and inhibitors have only been shown on iron absorption from dietary iron (up to 10mg). Also, the effect of the diurnal hepcidin increase on absorption from an iron supplement given in the afternoon without a preceding morning dose is unclear. Whether AA also increases iron bioavailability from a supplemental iron dose and whether a cup of coffee, a breakfast or iron administration in the afternoon decreases iron bioavailability from a supplemental dose is uncertain.
Status | Completed |
Enrollment | 35 |
Est. completion date | December 9, 2022 |
Est. primary completion date | December 9, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Female, 18 to 45 years old, - SF levels <30 µg/L, - Body weight < 70 kg - Normal Body Mass Index (18.5-25 kg/m2), - Signed informed consent. Exclusion Criteria: - Anemia (Hb < 12 g/dL) - Elevated CRP > 5 mg/L, - Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) affecting iron metabolism, - Continuous/long-term use of medication during the whole study, which may interfere with iron absorption, gut physiology and iron metabolism, - Consumption of mineral and vitamin supplements since screening and over the study period until last blood sample collection, - Difficulties with blood sampling, - Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months, - Known hypersensitivity or allergy to iron capsules in the given amount (ferrous fumarate, brilliant blue FCF (E133), titandioxide (E171) and sodium lauryl sulfate) - Pregnancy, breastfeeding - Women who intend to become pregnant during the course of the study, - Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse, - Smokers (> 1 cigarette per week), - Participant is likely to be absent on one the study appointments, - Inability to follow the procedures of the study, e.g. due to language problems, self-reported psychological disorders, etc. of the participant. |
Country | Name | City | State |
---|---|---|---|
Switzerland | ETH Zurich; Human Nutrition Laboratory; Institute of Food, Nutrition and Health | Zürich |
Lead Sponsor | Collaborator |
---|---|
Swiss Federal Institute of Technology |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fractional iron absorption [percent] | Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products. Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements. | Day 22 | |
Primary | Fractional iron absorption [percent] | Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products. Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements. | Day 43 | |
Primary | Total iron absorption [mg] | Total iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products. Total iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements. | Day 22 | |
Primary | Total iron absorption [mg] | Total iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products. Total iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements. | Day 43 | |
Secondary | Hemoglobin (Hb) | Iron status marker | Day 1, 22, 26 and 43 | |
Secondary | Serum ferritin (SF) | Iron status marker | Day 1, 22, 26 and 43 | |
Secondary | Serum transferrin receptor (sTfR) | Iron status marker | Day 1, 22, 26 and 43 | |
Secondary | Serum iron (SFe) | Iron status marker | Day 1, 22, 26 and 43 | |
Secondary | Total iron binding capacity (TIBC) | Iron status marker | Day 1, 22, 26 and 43 | |
Secondary | Hepcidin | Iron regulatory protein | Day 1, 22 and 26 | |
Secondary | C-reactive protein (CRP) | Inflammation marker | Day 1, 22, 26 and 43 | |
Secondary | Alpha-1-acid-glycoprotein (AGP) | Inflammation marker | Day 1, 22, 26 and 43 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06027801 -
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
|
N/A | |
Completed |
NCT02282553 -
Gastric Capsule Examination for Iron Deficiency Anaemia
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT04913649 -
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
|
Phase 4 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01307007 -
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
|
Phase 2 | |
Completed |
NCT00982007 -
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT00198848 -
Iron Supplementation Among Adolescent Girls in India
|
N/A | |
Completed |
NCT01166451 -
The Anemia Control Program: High or Low Iron Supplementation
|
N/A | |
Recruiting |
NCT03893045 -
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
|
Phase 3 | |
Recruiting |
NCT03817957 -
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
|
Phase 3 | |
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Completed |
NCT03618914 -
Anemia and Inflammation
|
||
Completed |
NCT03940430 -
Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT05153278 -
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
|